ArticleCureus2026
Assessment of Preoperative Serum Vitamin D Levels in Differentiated Thyroid Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWith the rising incidence of differentiated thyroid cancer (DTC), identifying its risk factors has become increasingly important. Vitamin D deficiency (VDD) is a recognized risk factor for several other types of cancer.
objectiveThis study aims to assess the association between preoperative serum 25-hydroxyvitamin D (25(OH)D) levels and DTC and, secondarily, to evaluate the association between vitamin D (VIT D) supplementation and DTC. MATERIALS AND
methodsThis retrospective case-control study included patients who underwent thyroidectomy at a tertiary care institute from January 2016 to January 2022. Preoperative serum 25(OH)D levels and histopathology of the resected thyroid were evaluated. Multivariable logistic regression analysis was performed to determine the association between serum 25(OH)D levels and DTC.
resultsA total of 633 patients were included (mean age, 46.83 ± 13.8 years; 530 (83.7%) were female), comprising 325 patients with malignant thyroid nodules and 308 patients with benign thyroid nodules who served as controls. The malignant group had significantly higher serum 25(OH)D levels than the controls (p = 0.037). However, 25(OH)D categories (deficient, inadequate, normal, and high) did not differ significantly between groups. Patients taking VIT D supplements were less likely to have DTC than those not taking supplements (45.5% vs. 57.5%, p = 0.003). In multivariable regression analysis, patients who took VIT D supplements had 37% lower odds of DTC (OR = 0.634; 95% CI = 0.460-0.873).
conclusionsSerum 25(OH)D levels were not significantly associated with DTC. However, VIT D supplementation was independently associated with lower odds of DTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.